Carol E Koro

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication
    Carol E Koro
    Worldwide Epidemiology, GlaxoSmithKline, Upper Providence, PA, USA
    Pharmacoepidemiol Drug Saf 14:697-703. 2005
  2. ncbi An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients
    Carol E Koro
    School of Pharmacy, University of Maryland, 506 W Fayette St, Suite 201, Baltimore, MD 21201, USA
    Arch Gen Psychiatry 59:1021-6. 2002
  3. ncbi Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report
    Carol E Koro
    GlaxoSmithKline, Upper Providence, Pennsylvania, USA
    Diabetes Care 27:17-20. 2004
  4. ncbi Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study
    Carol E Koro
    Pharmaceutical Health Services Research Department, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
    BMJ 325:243. 2002
  5. ncbi An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients
    Carol E Koro
    GlaxoSmithKline, Collegeville, PA 19426, USA
    Pharmacoepidemiol Drug Saf 17:989-96. 2008
  6. ncbi The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis
    Carol E Koro
    Worldwide Epidemiology, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
    Clin Ther 30:535-42. 2008
  7. ncbi Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States
    Carol E Koro
    GlaxoSmithKline, Worldwide Epidemiology, Collegeville, Pennsylvania 19426, USA
    Clin Ther 31:2608-17. 2009
  8. ncbi Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. from 1988 to 2002
    Tao Fan
    Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, 21201, USA
    Diabetes Care 29:1924-5. 2006
  9. ncbi Major CHD risk factors predominate among African-American women who are eligible for lipid-lowering drug therapy under the new ATP III guidelines
    Carol E Koro
    University of Maryland, Pharmaceutical Health Services Research Department, Baltimore, MD, USA
    Eur J Cardiovasc Prev Rehabil 11:376-81. 2004
  10. ncbi The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events
    Carol E Koro
    GlaxoSmithKline, Inc, Collegeville, PA, USA
    Am Heart J 151:755.e1-755.e6. 2006

Detail Information

Publications22

  1. ncbi Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication
    Carol E Koro
    Worldwide Epidemiology, GlaxoSmithKline, Upper Providence, PA, USA
    Pharmacoepidemiol Drug Saf 14:697-703. 2005
    ..This study assesses the effect of the type of antidiabetic treatment on the risk of developing congestive heart failure (CHF) in type 2 diabetes...
  2. ncbi An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients
    Carol E Koro
    School of Pharmacy, University of Maryland, 506 W Fayette St, Suite 201, Baltimore, MD 21201, USA
    Arch Gen Psychiatry 59:1021-6. 2002
    ..Previous studies have suggested an association between olanzapine treatment and hyperlipidemia. We evaluated this association using a large health care database...
  3. ncbi Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report
    Carol E Koro
    GlaxoSmithKline, Upper Providence, Pennsylvania, USA
    Diabetes Care 27:17-20. 2004
    ..S. adult diagnosed type 2 diabetes population between the National Health and Nutrition Examination Survey (NHANES) III (1988-1994) and the initial release of NHANES 1999-2000...
  4. ncbi Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study
    Carol E Koro
    Pharmaceutical Health Services Research Department, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
    BMJ 325:243. 2002
    ..2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8). CONCLUSION: Olanzapine is associated with a clinically important and significant increased risk of diabetes...
  5. ncbi An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients
    Carol E Koro
    GlaxoSmithKline, Collegeville, PA 19426, USA
    Pharmacoepidemiol Drug Saf 17:989-96. 2008
    ..To determine the likelihood of myocardial infarction (MI) in type 2 diabetic patients exposed to rosiglitazone and pioglitazone, separately, compared to other antidiabetic therapies...
  6. ncbi The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis
    Carol E Koro
    Worldwide Epidemiology, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
    Clin Ther 30:535-42. 2008
    ....
  7. ncbi Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States
    Carol E Koro
    GlaxoSmithKline, Worldwide Epidemiology, Collegeville, Pennsylvania 19426, USA
    Clin Ther 31:2608-17. 2009
    ....
  8. ncbi Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. from 1988 to 2002
    Tao Fan
    Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, 21201, USA
    Diabetes Care 29:1924-5. 2006
  9. ncbi Major CHD risk factors predominate among African-American women who are eligible for lipid-lowering drug therapy under the new ATP III guidelines
    Carol E Koro
    University of Maryland, Pharmaceutical Health Services Research Department, Baltimore, MD, USA
    Eur J Cardiovasc Prev Rehabil 11:376-81. 2004
    ..We studied the cardiovascular risk factor distributions among African-American men and women deemed eligible for lipid-lowering treatment under the new Adult Treatment Panel Guidelines (ATPIII)...
  10. ncbi The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events
    Carol E Koro
    GlaxoSmithKline, Inc, Collegeville, PA, USA
    Am Heart J 151:755.e1-755.e6. 2006
    ....
  11. ncbi Atypical antipsychotic therapy and hyperlipidemia: a review
    Carol E Koro
    GlaxoSmithKline, Upper Providence, Pennsylvania, USA
    Essent Psychopharmacol 6:148-57. 2005
    ..Patients with persistent dyslipidemia should be referred for lipid-lowering therapy or switched to a less lipid-enhancing antipsychotic agent...
  12. ncbi An assessment of the association between carvedilol exposure and severe hypersensitivity reactions, angioedema, and anaphylactic reactions: a retrospective nested case-control analysis
    Carol E Koro
    GlaxoSmithKline, 1250 S Collegeville Road, Collegeville, PA 19426, USA
    Clin Ther 34:870-7. 2012
    ..Most of the available information addresses the potential for increased severity of anaphylaxis or poor response to treatments among patients receiving β-blocking agents...
  13. ncbi New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population
    Donald O Fedder
    University of Maryland, Pharmaceutical Health Services Research Department, Baltimore, MD, USA
    Circulation 105:152-6. 2002
    ..We studied the impact of these changes on the size, sex, and age distribution of the target US population using data from the Third Annual National Health and Nutrition Survey (NHANES III) (1988 to 1994)...
  14. ncbi Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007
    Alexander M Walker
    World Health Information Science Consultants LLC, Wellesley, MA 02481, USA
    Pharmacoepidemiol Drug Saf 17:760-8. 2008
    ..The risk of coronary heart disease (CHD) in users of antidiabetic agents must be quantified to permit reasoned therapeutic choices...
  15. ncbi The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy
    Catherine B Johannes
    i3 Drug Safety, Auburndale, MA, USA
    Pharmacoepidemiol Drug Saf 16:504-12. 2007
    ..To evaluate whether the risk of coronary heart disease (CHD) differs among adult diabetic patients treated with thiazolidinediones (TZDs) and similar patients treated with combined oral metformin and sulfonylurea (M + S) therapy...
  16. ncbi The incidence of congestive heart failure in type 2 diabetes: an update
    Gregory A Nichols
    Kaiser Permanente Center for Health Research, Portland, Oregon 97227 1098, USA
    Diabetes Care 27:1879-84. 2004
    ....
  17. ncbi The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up
    Gregory A Nichols
    Kaiser Permanente Center for Health Research, Portland, Oregon 97227 1098, USA
    Clin Ther 28:243-50. 2006
    ..However, whether fibrates provide a CVD risk reduction independent of changes in the traditional lipoprotein fractions and other known CVD risk factors is not clear...
  18. ncbi The incidence of congestive heart failure associated with antidiabetic therapies
    Gregory A Nichols
    Kaiser Permanente Center for Health Research, 3800 N Interstate Avenue, Portland, OR 97227 1098, USA
    Diabetes Metab Res Rev 21:51-7. 2005
    ..Our objectives were to estimate the CHF risk associated with specific therapies for diabetes and to determine the differences in incidence rates of CHF associated with adding various antidiabetic agents...
  19. ncbi The effects of antipsychotic therapy on serum lipids: a comprehensive review
    Jonathan M Meyer
    University of California, San Diego VAMC MC 116A, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Schizophr Res 70:1-17. 2004
    ....
  20. ncbi Thiazolidinedione-associated congestive heart failure and pulmonary edema
    Steven J Bowlin
    Mayo Clin Proc 79:572, 575; author reply 575-7. 2004
  21. ncbi Primary prevention lipid-lowering drug therapy
    Donald O Fedder
    Circulation 106:e35-6; author reply e35-6. 2002
  22. ncbi The metabolic syndrome and schizophrenia: a review
    Jonathan Meyer
    University of California-San Diego, San Diego, CA, USA
    Int Rev Psychiatry 17:173-80. 2005
    ..This article describes and summarizes the information available on metabolic syndrome in the mental illness disease area and the proposed mechanisms for the increased prevalence of the metabolic syndrome in this population...